| Literature DB >> 33937533 |
Bkhtiar Khosravi1, Borhan Moradvaesi2, Masomeh Abedini3, Shirin Behzadi3, Awat Karimi3.
Abstract
Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Some patients with COVID-19 show widely neurological manifestations including stroke. We report a child who was hospitalized due to seizures and was later diagnosed with COVID-19. Acute infarction was seen in the right putamen, globus pallidus, and the posterior part of the insula. A small focal dilatation within M1 segment of the left middle cerebral artery (MCA) was also observed. According to the present case report, COVID-19 infection may contribute to the occurrence and development of ischemic stroke.Entities:
Keywords: COVID-19; Coronavirus; Pediatric patients; SARS-CoV-2; Stroke
Year: 2021 PMID: 33937533 PMCID: PMC8079941 DOI: 10.1016/j.ensci.2021.100345
Source DB: PubMed Journal: eNeurologicalSci ISSN: 2405-6502
Clinical findings in patient with ischemic stroke in the setting of COVID-19.
| In patient | Normal range | |
|---|---|---|
| white blood cell | 6.8 × 109/L | 5 to 11 × 109/L |
| white blood cell differential | 60% neutrophils | 20.0%–50.0% |
| 40% lymphocytes | 40.0%–75.0% | |
| hemoglobin | 13 g/dL | in children: 11–13 g/dL |
| prothrombin time (PT) | 12 s | 10–12 s |
| partial thromboplastin time (PTT) | was 26 s | 25–35 s |
| factor XIII | more than 30% | 50% to 150% |
| erythrocyte sedimentation rate (ESR) | 12 mm/h | 0 to 10 mm/h |
| lactate dehydrogenase (LDH) | 318 units/L | 60 to 170 units/L |
| D-dimer | was less than 200 | for 2–12 year-old children: 4–227 ng/L) |
| triglyceride | 119 mg/dL | 150 to 199 mg/dL |
| cholesterol | 149 mg/dL | below 200 mg/dL |
| LDL | 125 U/L | 140 to 280 units per liter U/L |
| HDL | 43 mg/dl | less than 45 mg/dl |
| ammonia (plasma) | 58 μmol/L | 50 to 100 μmol/L |
| lactate (plasma) | 1.4 mmol/L | for 2–18 year-old individuals: 1.0–2.4 mmol/L |
| pyruvate | 0.95 mmol/L | 0.08–0.16 mmol/L |
| anti-cardiolipin antibodies (ACA) | 2.5 | (reference range previously listed as IgG: 0–14 (negative) for IgG (immunoglobulin G |
| 3.1 | (reference range previously listed as IgM: 0–12 (negative) for IgM (immunoglobulin M) | |
| beta-2 glycoprotein 1 antibodies | 1.4 for IgG | positive results: >40 U/mL for IgG |
| 0.4 for IgM | positive results: >40 U/mL for IgM | |
| lupus anticoagulant | 34.7 | up to 46.1 s |
| aPTT-LA (lupus sensitive reagent) | 31.6 | 31 to 47 GPL |
| protein C | 0.73 U/ml | 0.72–1.23 U/ml |
| Protein S | 0.79 U/ml | 0.60–1.60 U/ml |
| antithrombin III (ATIII) | 133% | 80% to 120% |
| Varicella-zoster virus (VZV) | 686.90 for IgG | Less than 135 mlU/ml |
| 0.25 for IgM | Less than 0.4 | |
| fluorescent antinuclear antibodies (FANA) | negative | No reaction at 1/100 |
| Anti-double-stranded (ds)DNA antibodies IgG | 9.7 | Less than 100 IU/ml |
Fig. 1Infarct areas in the brain.
These images are from patient with ischemic stroke in the setting of COVID-19. The MRI showed an acute infarction in the right putamen, globus pallidus, and the posterior part of the insula.